Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03705845
PHASE1/PHASE2

Tocotrienols for Obesity of Postmenopausal Women

Sponsor: Texas Tech University Health Sciences Center

View on ClinicalTrials.gov

Summary

Postmenopausal women are at a risk of excessive weight gain, bone loss, hypertension, and metabolic syndrome. Obesity-induced chronic low-grade inflammation is initiated by excess nutrients in metabolic cells. Recent studies have indicated tocotrienols (one kind of vitamin E, a potent antioxidant) supplement may be good for mitigating negative impacts of obesity in postmenopausal women. The purpose of the study is to examine the effect of 24-week tocotrienols on obesity-associated outcome measurements in postmenopausal women. The investigators will enroll 60 qualified women at the start of the study and randomly assigned to no tocotrienols (placebo) or tocotrienols group for 24 weeks. Obesity-associated measurements will be recorded using blood, urine, adipose tissue, and fecal samples. All data will be analyzed statistically.

Official title: Actions of Dietary Tocotrienols on Obesity

Key Details

Gender

FEMALE

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2019-03-15

Completion Date

2025-12-30

Last Updated

2025-03-28

Healthy Volunteers

Yes

Interventions

DRUG

placebo softgel

Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.

DRUG

DeltaGold® Tocotrienol 70%

DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.

Locations (1)

Texas Tech University Health Sciences Center

Lubbock, Texas, United States